Cargando…
Discoidin Domain Receptor 1 (DDR1) tyrosine kinase is upregulated in PKD kidneys but does not play a role in the pathogenesis of polycystic kidney disease
Tolvaptan is the only drug approved to slow cyst growth and preserve kidney function in patients with autosomal dominant polycystic kidney disease (ADPKD). However, its limited efficacy combined with significant side effects underscores the need to identify new and safe therapeutic drug targets to s...
Autores principales: | Soomro, Irfana, Hong, Aram, Li, Zhai, Duncan, James S., Skolnik, Edward Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602183/ https://www.ncbi.nlm.nih.gov/pubmed/31260458 http://dx.doi.org/10.1371/journal.pone.0211670 |
Ejemplares similares
-
PKD1 and PKD2 mutations in Slovenian families with autosomal dominant polycystic kidney disease
por: Vouk, Katja, et al.
Publicado: (2006) -
Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations
por: Losekoot, Monique, et al.
Publicado: (2020) -
PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression
por: Lakhia, Ronak, et al.
Publicado: (2022) -
Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer
por: Quan, Jinhua, et al.
Publicado: (2011) -
Identification of novel PKD1 and PKD2 mutations in Korean patients with autosomal dominant polycystic kidney disease
por: Choi, Rihwa, et al.
Publicado: (2014)